Loading...

MANKIND Mankind Pharma Ltd Earnings Reports Announcement

Mnkn

MNKN

Mankind Pharma Ltd

(MANKIND)

2025 Announcement

Show Summary

Show Summary

ESOP Share Allotment

ESG Rating Update

New Subsidiary Established

Investor Conference

Investor Conference

Financial Results Published

Investor Call Recording

Auditor Appointments

Subsidiary in Sri Lanka

Investor Presentation

Q4 FY25 Results

Tax Demand Received

Monitoring Report

Income Tax Demand

Tax Demand Order

Investor Call Scheduled

Tax Demand Notice

Tax Orders Received

Annual Compliance Report

Acquisition Announcement

Regulatory Compliance

Share Capital Increase

Amalgamation Effective Date

Amalgamation Approved

Income Tax Orders

Credit Rating Withdrawal

Tax Penalty Order

Tax Demand Notification

Amalgamation Approval

Credit Rating Update

Investor Conference Notice

Investor Conference Intimation

Director Departure

Stake Sale Completed

Stake Sale Announcement

Investor Meeting

Investor Conferences

Q3 Earnings Call

Monitoring Agency Report

Financial Results Published

Investor Presentation

Q3FY25 Financial Results

Financial Results Update

Commercial Paper Redemption

GST Penalty Appeal

Commercial Paper Update

Redemption Announcement

Investor Call Announcement

Management Changes

Management Appointment

Management Changes

Share Pledge Created

Compliance Certificate

Regulatory Penalty Appeal

Equity Share Allotment

Qualified Institutional Pla...

Fundraising via QIP

Board Meeting Outcome

Penalty Notification

Investor Meeting

Management Appointment

CGST Penalty Appeal

Postal Ballot Notice

Share Pledge Announcement

Auditor Appointment

Earnings Call Transcript

Equity Shares Allotted

Financial Results Released

Investor Conference

Credit Rating Reaffirmed

Investor Call Update

Management Change

Financial Results Q2

Corporate Governance Update

Investor Presentation

Investor Conference Call

Board Meeting Notice

Acquisition Completed

Mankind Acquires BSV

Commercial Papers Issued

Regulatory Certificate

Acquisition Update

OTC Business Transfer

Credit Rating Update

Credit Rating Update

Fundraising Approval

Investor Meetings

Business Transfer Agreement

Investor Presentation

Penalty Notification

Penalty Notification

Investor Presentation

Investor Presentation

Investor Conference

Investor Meeting

Credit Rating Reaffirmed

Investor Meeting

Acquisition Outcome

Financial Results Publication

Investor Conference Call Ou...

Investor Meeting

Financial Results Announcement

Investor Presentation

Acquisition Outcome

Rescheduled Conference Call

Investor Conference

Investor Presentation

Acquisition Announcement

Acquisition Approval

Investor Conference Call

Certificate Submission

Newspaper Advertisement

Credit Rating Update

Newspaper Publication

Penalty Notification

Investor Conference

Newspaper Advertisement

Investor Conference Call

Financial Results Publication

Investor Presentation

Financial Results

Authorized Share Capital In...

Outcome of Board Meeting

Financial Decisions

Appointment of Auditor

Penalty Imposed

Conference Call Announcement

Compliance Report Submission

Penalty Imposed

Penalty Imposed

Credit Rating Assignment

Certificate Submission

Amalgamation Update

Compliance Certificate

Slump Sale Approval

Volume Increase

Investor Meetings

Pharma Partnership

Approval for Reclassification

Court Order Payment

Equity Share Sale

Conference Participation

Conference Call Transcript

Equity Share Sale

Investor Conference Call - ...

Financial Results Publication

Investor Presentation

Financial Results

Investor Conference Call

Investor Presentation

Certificate Submission

Participation in Conference

Investment in Actimed Thera...

Investor Meeting

Reclassification Application

Investor Conference Partici...

Investor Meeting

Investor Conference Partici...

Investor Conference Call

Investor Conference

Conference Call

Financial Results Publication

Investor Presentation

Pharmas Financial Results

Financial Results and Schem...

Reclassification of Shareho...

Investor Conference Call

Management Appointment

Resumption of Operations

Certificate Submission

Disruptions at Manufacturin...

Operations Commencement

Investor Meetings

Investor Meetings

Incorporation of Subsidiary

Conference Call

Investor Meetings

Financial Statements

Financial Statements

Financial Statements

Appointments, Reappointment...

External Links:

Data:

Mankind Pharma reported a 24% increase in revenue for Q3FY25, reaching INR 3,230 Crore, with an adjusted EBITDA margin of 27.7%. The company has shown significant growth in its OTC business and strong recovery in chronic products.

AI Assistant

Mankind Pharma Ltd

2025

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.